Fairvalue-Calculator Fairvalue-Calculator
EN DE

Hangzhou Zhongtai Cryogenic Technology Corporation (300435) Fair Value & Analysis

Industrials · CN · Market cap 8.1B CNY

Price¥23.94
Fair Value¥24.52
Upside+2.4%
Quality93/100
Evidence: High Range ¥18.39 – ¥30.65

Analysis

Hangzhou Zhongtai Cryogenic Technology Corporation (300435) currently trades at ¥23.94, while our model-based Fair Value estimate is ¥24.52 — implying the stock looks roughly 2.4% undervalued today. We read business quality at 93/100 (high quality), in the Industrials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Hangzhou Zhongtai Cryogenic Technology Corporation develops, designs, manufactures, and sells cryogenic equipment in China. The company provides engineering services, such as natural gas engineering, air separation, syngas cryogenic separation, olefins separation, specialty gas, and chemical gas purification; manufacturers and sells plate-fin heat exchanger, spiral wound heat exchanger, cold box, distillation column, cryogenic vessel, and skid integration products; and offers EPC services, including natural gas liquefaction plant, natural gas processing plant, air separation plant, rare gas separation, and purification separation plant. It also exports its products to the United States, Europe, Africa, and Asia. Hangzhou Zhongtai Cryogenic Technology Corporation was founded in 2006 and is headquartered in Hangzhou, China.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.